News
-
-
PRESS RELEASE
TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update
TuHURA Biosciences, Inc. provides a business update on its innovative cancer immunotherapy technologies, including IFx-2.0 Phase 3 trial for Merkel Cell Carcinoma, potential KVA12123 acquisition, and key management appointments -
-
-
REGULATED PRESS RELEASE
Statement of transactions in own shares from November 18, 2024 to November 22, 2024
-
-
PRESS RELEASE
EQ Inc. Reports Third Quarter Financial Results
EQ Works reports significant improvements in adjusted EBITDA sequentially and year over year with revenue holding steady, gross margin increasing, and successful cost optimization efforts driving profitability. Company secures financing and legal settlement inflow supports financial position -
-
-
